Q-omics provides the consensus-scored TBX2 profile across patient tissues and cancer cell-line models. TBX2 expression is associated with patient survival in 26 of 34 cancer types, with the highest sampling consensus in KIRP. Among the 18 cancer types available for tumor–normal comparison, TBX2 is differentially expressed in 13, with the highest sampling consensus in HNSC. Additionally, TBX2 protein abundance shows 17,242 significant protein co-abundance associations, with the highest sampling consensus in LUAD. Together, these results highlight KIRP, HNSC, and LUAD as cancer lineages where TBX2 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for TBX2 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes TBX2 survival associations across molecular data types. TBX2 RNA expression shows survival associations in the most cancer types (26), followed by mutation status (5) and mass-spec protein abundance (6). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible TBX2 RNA expression–survival associations across cancer types. High TBX2 expression shows unfavorable associations in KIRP, ACC, LGG and SARC, but favorable associations in UVM and BLCA. The KIRP Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify KIRP as the clearest survival context for TBX2 RNA expression.
This table summarizes TBX2 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 13, while mass-spec protein shows differences in 2. The strongest signals are observed in HNSC for RNA and LUAD for protein.
This table ranks reproducible tumor–normal expression differences for TBX2. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. TBX2 shows lower tumor expression in KIRP, LUAD and LUSC and higher tumor expression in HNSC, LIHC and STAD. The HNSC box plot shows higher TBX2 RNA expression in tumor versus normal tissue (log2 FC = +1.573, t-test p < 0.001).
This table shows molecular features associated with TBX2 in patient tissues and cancer cell lines. In patient samples, TBX2 shows the broadest associations at the RNA and protein expression levels, with LUAD recurring as the lineage with the largest associated feature set. In cancer cell lines, TBX2 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in LUNG_SCLC, while CRISPR and shRNA rows add functional-dependency signals in SKIN and LARGE_INTESTINE.
